Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRONASDAQ:SRRKNASDAQ:VKTXNASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$45.31-0.7%$41.71$17.86▼$58.40$3.61B-0.18875,505 shs1.42 million shsSRRKScholar Rock$32.76-0.5%$32.33$6.76▼$46.98$3.11B0.561.26 million shs984,136 shsVKTXViking Therapeutics$28.61-0.9%$26.16$18.92▼$81.86$3.21B0.844.09 million shs3.45 million shsXNCRXencor$10.86-1.5%$11.46$7.16▼$27.24$772.71M0.9622,385 shs555,677 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics+5.97%+15.04%+12.67%-17.61%+129.31%SRRKScholar Rock+0.43%+0.98%+2.36%-18.54%+124.34%VKTXViking Therapeutics+3.33%+11.73%+19.54%-14.31%-63.72%XNCRXencor+4.16%+1.22%+3.57%-40.43%-47.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics3.7928 of 5 stars3.51.00.04.73.41.70.0SRRKScholar Rock4.0498 of 5 stars3.50.00.04.43.43.30.6VKTXViking Therapeutics4.4778 of 5 stars4.52.00.04.72.33.30.0XNCRXencor3.24 of 5 stars3.60.00.03.92.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$76.2968.36% UpsideSRRKScholar Rock 3.00Buy$42.6730.24% UpsideVKTXViking Therapeutics 3.00Buy$87.15204.63% UpsideXNCRXencor 3.13Buy$32.86202.55% UpsideCurrent Analyst Ratings BreakdownLatest XNCR, SRRK, AKRO, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025XNCRXencorWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$31.004/29/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$104.004/28/2025VKTXViking TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$95.00 ➝ $75.004/24/2025VKTXViking TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.004/24/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/21/2025XNCRXencorWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/17/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/8/2025VKTXViking TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$30.003/26/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.003/25/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$9.61 per shareN/ASRRKScholar Rock$33.19M93.63N/AN/A$3.12 per share10.50VKTXViking TherapeuticsN/AN/AN/AN/A$3.48 per shareN/AXNCRXencor$110.49M6.99N/AN/A$10.99 per share0.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$151.76M-$3.75N/AN/AN/AN/A-32.46%-29.83%5/9/2025 (Estimated)SRRKScholar Rock-$165.79M-$2.45N/AN/AN/AN/A-145.60%-91.83%5/6/2025 (Estimated)VKTXViking Therapeutics-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%N/AXNCRXencor-$126.09M-$3.51N/AN/AN/A-232.77%-30.92%-21.74%5/8/2025 (Estimated)Latest XNCR, SRRK, AKRO, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025AKROAkero Therapeutics-$1.00N/AN/AN/AN/AN/A5/8/2025Q1 2025XNCRXencor-$0.60N/AN/AN/A$23.44 millionN/A5/6/2025Q1 2025SRRKScholar Rock-$0.63N/AN/AN/AN/AN/A4/23/2025Q1 2025VKTXViking Therapeutics-$0.31-$0.41-$0.10-$0.41N/AN/A2/28/2025Q4 2024AKROAkero Therapeutics-$0.98-$0.99-$0.01-$0.99N/AN/A2/27/2025Q4 2024XNCRXencor-$0.81-$0.62+$0.19-$0.62$17.14 million$52.79 million2/5/2025Q4 2024VKTXViking Therapeutics-$0.27-$0.32-$0.05-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0517.2517.25SRRKScholar Rock0.633.883.88VKTXViking TherapeuticsN/A36.4736.47XNCRXencor0.016.236.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/ASRRKScholar Rock91.08%VKTXViking Therapeutics76.03%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.94%SRRKScholar Rock13.30%VKTXViking Therapeutics4.10%XNCRXencor5.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.62 million64.26 millionOptionableSRRKScholar Rock14094.86 million75.64 millionOptionableVKTXViking Therapeutics20112.29 million106.20 millionOptionableXNCRXencor28071.15 million66.32 millionOptionableXNCR, SRRK, AKRO, and VKTX HeadlinesRecent News About These CompaniesWill Xencor (XNCR) Report Negative Q1 Earnings? What You Should KnowMay 1 at 11:06 AM | zacks.comTCG Crossover Management LLC Acquires 25,000 Shares of Xencor, Inc. (NASDAQ:XNCR)May 1 at 8:03 AM | marketbeat.comPrice T Rowe Associates Inc. MD Purchases 107,350 Shares of Xencor, Inc. (NASDAQ:XNCR)April 30 at 5:10 AM | marketbeat.comBarclays PLC Boosts Stock Position in Xencor, Inc. (NASDAQ:XNCR)April 26, 2025 | marketbeat.comWilliam Blair Predicts Xencor's Q1 Earnings (NASDAQ:XNCR)April 25, 2025 | marketbeat.comInvesco Ltd. Sells 156,130 Shares of Xencor, Inc. (NASDAQ:XNCR)April 25, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Shares Down 2.7% - Here's WhyApril 24, 2025 | marketbeat.comQ1 Earnings Estimate for Xencor Issued By William BlairApril 24, 2025 | americanbankingnews.comXencor (NASDAQ:XNCR) Stock Price Up 9.3% - Here's What HappenedApril 23, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Now Covered by William BlairApril 23, 2025 | marketbeat.comWilliam Blair starts Xencor stock with Outperform ratingApril 23, 2025 | uk.investing.comWilliam Blair Initiates Coverage of Xencor (XNCR) with Outperform RecommendationApril 22, 2025 | msn.comBrokerages Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $33.86April 22, 2025 | americanbankingnews.comWilliam Blair Begins Coverage on Xencor (NASDAQ:XNCR)April 22, 2025 | americanbankingnews.comXencor initiated with an Outperform at William BlairApril 21, 2025 | markets.businessinsider.comXencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Buy" by AnalystsApril 20, 2025 | marketbeat.comXencor participates in a conference call with JPMorganApril 19, 2025 | markets.businessinsider.comXencor (NASDAQ:XNCR) Stock Price Up 4.9% - What's Next?April 17, 2025 | marketbeat.comGeode Capital Management LLC Acquires 179,526 Shares of Xencor, Inc. (NASDAQ:XNCR)April 17, 2025 | marketbeat.comNorges Bank Buys New Position in Xencor, Inc. (NASDAQ:XNCR)April 13, 2025 | marketbeat.comXencor, Inc.: No Major Near Term CatalystsApril 11, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonViking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold GainsViking Therapeutics Stock May Struggle After As-Expected ReportBy Chris Markoch | April 25, 2025View Viking Therapeutics Stock May Struggle After As-Expected ReportXNCR, SRRK, AKRO, and VKTX Company DescriptionsAkero Therapeutics NASDAQ:AKRO$45.31 -0.30 (-0.66%) Closing price 04:00 PM EasternExtended Trading$42.28 -3.03 (-6.69%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Scholar Rock NASDAQ:SRRK$32.76 -0.15 (-0.46%) Closing price 04:00 PM EasternExtended Trading$32.76 0.00 (-0.02%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Viking Therapeutics NASDAQ:VKTX$28.61 -0.26 (-0.90%) Closing price 04:00 PM EasternExtended Trading$28.69 +0.08 (+0.29%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.Xencor NASDAQ:XNCR$10.86 -0.16 (-1.45%) Closing price 04:00 PM EasternExtended Trading$10.85 -0.01 (-0.09%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
